ABUS three-lens brief
Evidence-based stock research on ABUS. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
Underperforming SPY by 18.5pp over 30 days. · Trading >3% below the 50-day MA — short-term weakness.
- Trading >3% below the 50-day MA — short-term weakness.
- Underperforming SPY by 18.5pp over 30 days.
- P/E of 3.5 — trading at a value multiple.
- Reported earnings on 2026-11-12.
- Earnings in today (2026-11-12).
ABUS closed at $3.88 (+1.57%) as of 2026-11-12. Market cap: $594.78M. P/E (trailing) 3.5. Price is below the 50-day MA and below the 200-day MA. Positives: p/E of 3.5 — trading at a value multiple.. Concerns: trading >3% below the 50-day MA — short-term weakness.; underperforming SPY by 18.5pp over 30 days.. Last quarter: Revenue $422.4K, net income $83.51M, free cash flow $334.96M. Watching for: 2026-11-12 earnings release (today).
Why three lenses on ABUS, not one.
A single reasoning model has blind spots it doesn’t know about. We examine ABUS across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/ABUS" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath ABUS brief"></iframe>